Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRVL Prevail Therapeutics (PRVL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Prevail Therapeutics Stock (NASDAQ:PRVL) 30 days 90 days 365 days Advanced Chart Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Prevail Therapeutics alerts:Sign Up Key Stats Today's Range$23.00▼$23.0050-Day Range$22.91▼$23.2052-Week Range$9.02▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Receive PRVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PRVL Stock News HeadlinesIllinois Takes on the Ducks: Will Toughness Prevail?October 25, 2024 | msn.comMedtronic’s Prevail DCB pivotal trial receives FDA IDE approvalOctober 25, 2024 | msn.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Slaughter to Prevail’s Epic New Song ‘Behelit’ Has Fans Reacting to Different StyleOctober 16, 2024 | msn.comLiberty vs. Aces Series Analysis: Who Will Prevail?October 4, 2024 | msn.comHalestorm & I Prevail's ‘Can U See Me in the Dark?' Tops Mainstream Rock Airplay ChartSeptember 25, 2024 | msn.comPrevail Partners and Prevail InfoWorks Enter Into Strategic Investment and Clinical Alliance With Kairos Pharma, Ltd.September 25, 2024 | finance.yahoo.comUnited States Asking Turkey to Prevail on Iran to De-Escalate Tensions, Envoy SaysAugust 13, 2024 | usnews.comSee More Headlines PRVL Stock Analysis - Frequently Asked Questions How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) released its quarterly earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.09. When did Prevail Therapeutics IPO? Prevail Therapeutics (PRVL) raised $126 million in an initial public offering on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prevail Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Alector (ALEC), Advanced Micro Devices (AMD), Atreca (BCEL) and Homology Medicines (FIXX). Company Calendar Last Earnings11/13/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRVL CUSIPN/A CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.57% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Miscellaneous Outstanding Shares34,246,000Free FloatN/AMarket Cap$787.66 million OptionableNot Optionable Beta1.59 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:PRVL) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prevail Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
